Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Status:
RECRUITING
Trial end date:
2027-05-25
Target enrollment:
Participant gender:
Summary
This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences